Compare · AKCA vs CHMA
AKCA vs CHMA
Side-by-side comparison of Akcea Therapeutics, Inc. (AKCA) and Chiasma, Inc. (CHMA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKCA and CHMA operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- Company
- Akcea Therapeutics, Inc.
- Chiasma, Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Chiasma, Inc.
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
Latest AKCA
- Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
- IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, DCOM, STND
- SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Investigations
- Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (NASDAQ: CGIX), Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), Otelco Inc. (NASDAQ: OTEL), Rosetta Stone Inc. (NYSE: RST), Varian Medical Systems, Inc. (NYSE: VAR), and Yintech Investment Holdings Limited (NASDAQ: YIN)
- Moore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law Firm
- WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England
- Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX)
- INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm – RST, CBMG, AIMT, AKCA
Latest CHMA
- Amryt Reports Q3 2022 Financial and Operational Results
- Amryt Reports Record Q2 2022 Results
- SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer
- Amryt Reports Record Q1 2022 Results
- Amryt Announces 22% growth in FY 2021 Revenues to $222.5M
- SEC Form EFFECT filed by Chiasma, Inc.
- SEC Form 15-12B filed by Chiasma, Inc.
- SEC Form 4: STONEPINE CAPITAL, L.P. returned 6,770,000 units of Common Stock to the company
- SEC Form SC 13G/A filed by Chiasma, Inc. (Amendment)
- SEC Form S-8 POS filed by Chiasma, Inc.